Business
    Next Score View the next score

    Mass. Movers

    HeartWare’s big gain is erased

    A patient undergoes a heart transplant.
    Seattle Times via AP/File 2012
    A patient undergoes a heart transplant.

    The stock’s swings were almost enough to quicken the pulse: The FDA on Tuesday approved a heart pump from HeartWare International Inc., of Framingham, for patients awaiting a heart transplant, and the shares rose 9 percent, the most in seven months. But on Wednesday, the stock fell nearly 9 percent. Similar ventricular assist devices have been approved previously, but HeartWare’s device is smaller and may be easier to implant. The pumps are intended to take over for a failing heart, extending patients’ lives or gaining time to find a heart donor.

    Advertisement